About
Bio
Impact factor:
Not presently indexed.
Journal ranking:
Not presently indexed.
Circulation:
A circulation figure is not currently available.
Aims of the journal:
Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 – 50% of adult patients with extrahepatic primary tumors.
Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy.
Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP2.
Content:
Studies on all types of primary and secondary hepatic cancers, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, fibrolamellar carcinoma and mesenchymal cancers of the liver
Clinical trials in hepatic oncology
Diagnosis and imaging
Epidemiology
Palliative care
Pathogenesis
Pathology
Pediatrics
Pharmacoeconomics, outcomes and comparative effectiveness research
Prognosis
Risk factors
Staging
Surveillance
Therapy, including surgery, chemotherapy, chemoembolisation, ablation, radiotherapy, hormonal and biological therapies
Translational research and biomarker studies
Editorial contacts:
The Editorial Board members can be viewed here
Manuscript submission:
Instructions for authors and editorial guidelines can be viewed here
Other Information:
Average Lead Time to Online Publication: 14 - 16 weeks
Editorial queries can also be directed to r.gunawardana@futuremedicine.com
For Drug Evaluations, contact h.ireland@futuremedicine.com
Email
email@cision.one
Website
site@cision.one
Social media
Location
United Kingdom
Frequency
upgrade
Circulation
upgrade
Sectors
Oncology
Bio
Impact factor: Not presently indexed. Journal ranking: Not presently indexed. Circulation: A circulation figure is not currently available. Aims of the journal: Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 – 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP2. Content: Studies on all types of primary and secondary hepatic cancers, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, fibrolamellar carcinoma and mesenchymal cancers of the liver Clinical trials in hepatic oncology Diagnosis and imaging Epidemiology Palliative care Pathogenesis Pathology Pediatrics Pharmacoeconomics, outcomes and comparative effectiveness research Prognosis Risk factors Staging Surveillance Therapy, including surgery, chemotherapy, chemoembolisation, ablation, radiotherapy, hormonal and biological therapies Translational research and biomarker studies Editorial contacts: The Editorial Board members can be viewed here Manuscript submission: Instructions for authors and editorial guidelines can be viewed here Other Information: Average Lead Time to Online Publication: 14 - 16 weeks Editorial queries can also be directed to r.gunawardana@futuremedicine.com For Drug Evaluations, contact h.ireland@futuremedicine.com
Website
Social media
Location
Frequency
Circulation
Sectors
Oncology
Most recent articles by Hepatic Oncology
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Explore outlets similar to Hepatic Oncology
-
OncologyLiveEstablished in 2000 as Oncology Net Guide and rebranded in March 2011 as OncLive. Written for physicians to enable them to keep up to date with the rapidly expanding amount of medical information and resources on oncology. Designed as a handbook for frequent referencing and written in an easy-to-understand style. Articles are quick-reading, timely, provides practical information and information about new medical treatments. Media Alert: Tuesday April 12th 2011 Oncology Net Guide has changed its name to OncLive. Anita Shaffer is Associate Editor in charge of the oncology research and technology magazine. She may be reached at +1 (609) 716 7777 Ext 192 and ashaffer@onclive.com
View
Targeted OncologyTargeted Oncology is an online resource for oncology news and research, carrying content from Intellisphere's printed oncology journals, Targeted Therapies and The Journal of Targeted Therapies.
ViewMMedical News TodayBackground and Format: Launched in 2003, Medical News Today is a website overseen by Healthline Media UK Ltd and is aimed at healthcare professionals and consumers. Covers health news, diseases, nutrition & diet and pain & aesthetics. For more information about advertising rates, the team can be reached here. Circulation: Source: Publisher.
ViewTThe Lancet OncologyImpact Factor: 26.509 (Source:Thomson Reuters Journal Citation 2016) Format and Background: The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice. Circulation: The Publisher does not disclose the circulation. Aims of the journal: The Lancet Oncology was launched in September 2000 with the aim of being a lively and informative monthly journal covering international issues relevant to clinical cancer specialists worldwide. In May 2005, the journal expanded to include original research and began publishing articles online first prior to print publication. In 2008, the journal expanded its online presence to include regular podcasts. The aim of The Lancet Oncology is to publish interesting, informative, and practice-changing articles on any topic connected with clinical oncology. Readership: Clinical cancer specialists worldwide. Content: Topics include, but are not limited to: Breast cancer Endocrine system cancer Gastrointestinal cancer Genitourinary cancer Gynaecological cancer Haematological cancer Head and neck cancer Neurooncology Paediatric oncology Thoracic oncology Sarcoma Skin cancer Epidemiology, cancer prevention, and cancer control Supportive care Imaging Health-care systems Manuscript submission: The journal publishes a range of article types that encompass all aspects of oncological medicine: Comment, Correspondence, News, Cancer and Society, Article, Meta-analysis, Review, Historical Review, Health-care Development, Personal View, and Debate. For further information for authors, click here. Online manuscripts submission here. Ad Rates: Can be viewed here the advertising team can be reached at lancet-ads@elsevier.com Other Information: The RSS feed can be viewed here Podcasts can be found here Information for the press can be viewed here
ViewJJAMA OncologySet to launch in February 2015, this medical journal aimed at physicians covers oncology. Will feature all aspects of medical, radiation, and surgical oncology and its subspecialties
ViewUse CisionOne to find more relevant outletsContact Hepatic Oncology and get access to over 850K accurate, up-to-date media profiles.
Discover the stories that impact your brand. In realtime.
CisionOne delivers relevant news, trends and conversations that matter to your brand with the world’s most comprehensive media monitoring service across Print, Online, TV, Radio, Social, Magazines, Podcasts and more.
